Refractory Kawasaki Disease, IP

NEMOURS CHILDREN'S HEALTH

Last Updated: 11/11/25

INCLUSION CRITERIA

- Patient meets definition for Refractory KD[1]

EXCLUSION CRITERIA

- KD patient that responded to standard treatment (see **KD Clinical Pathway**)

MEASURES

- Increase utilization of refractory KD pathway for patients that meet criteria (target - 80%)

[1]REFRACTORY KD

In a patient diagnosed with KD, Refractory is defined as **any** of the following:

- Persistent fever of any magnitude 24 to 36 hours after completion of IVIG therapy
- Return of fever of any magnitude after an afebrile period not explained by any cause other than KD (up to 2 weeks after the start of treatment)
- Other signs of failed initial therapy such as progressive coronary artery dilation or other manifestations of inflammation associated with KD (eg, nonexudative conjunctivitis)

[2]DISCHARGE CRITERIA

- Observed 36-48 hours after completion of treatment
- Afebrile for 36-48 hours
- Down trending CRP >36-48hr after completion of treatment
- Stable coronary measurements on at least 2 Echo's greater than 24 hrs. apart



Medication	Route	Dose	Max. per Dose	Duration
Aspirin MODERATE dose	PO/PR	30-50 mg/kg/**day** divided Q6h		Until 48 hours after resolution of fever
Aspirin LOW dose	PO	3-5 mg/kg once daily	325 mg	6-8 weeks, assess at follow-up. Discontinuation dictated by cardiology
Famotidine	IV	<3 months: 0.25 mg/kg/**dose** once daily ≥3 months: 0.25 mg/kg/**dose** twice daily	20 mg	Discontinue when off steroids and moderate dose aspirin
	PO	<3 months: 0.5 mg/kg/**dose** once daily ≥3 months: 0.5 mg/kg/**dose** twice daily		
Infliximab	IV	10 mg/kg once	n/a	
IVIG	IV	2 g/kg once	n/a	
Methylprednisolone/Prednisone/ Prednisolone	IV/PO	1 mg/kg/**dose** twice daily	30 mg	Consult with rheumatology for duration.

Abbreviations			
Abbreviation	**Terminology**	**Abbreviation**	**Terminology**
ALT	Alanine transaminase	**GI**	Gastrointestinal
CAA	Coronary Artery Aneurysm	**hrs**	Hours
CAs	Coronary Arteries	**ID**	Infectious Disease
CBC	Complete Blood Count	**IV**	Intravenous
CMP	Complete Metabolic Panel	**kg**	Kilogram
CRP	C-Reactive Protein	**LAD**	Left Anterior Descending
d	Day	**mg**	Milligram
ECHO	Echocardiogram	**PO**	By mouth
eg	For Example	**UA**	Urinalysis
g	Gram	**WBC**	White Blood Cell

VERSION MANAGEMENT

- Version 1.0 (11/11/2025): Go Live.

Questions about this pathway should be directed to **clinicalpathways@nemours.org**.

AUTHORS & REFERENCES

Delaware Valley Authors: Deepika Thacker, Annemarie Brescia, Emily Fingado
Central Florida Authors: Ameneh Ebadi

- Eleftherlou D, Levin M, Shingadia D et al. Management of Kawasaki Disease. *Arch Dis Child*. 2014 Jan;99(1):74-83
- Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. *Arthritis Care Res (Hoboken)*. 2022;74(4):538-548. doi:10.1002/acr.24838
- Jone PN, Tremoulet A, Choueiter N, et al. Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association [published correction appears in Circulation. 2025 Feb 25;151(8):e677-e679. doi: 10.1161/CIR.0000000000001313.]. *Circulation*. 2024;150(23):e481-e500. doi:10.1161/CIR.0000000000001295
- Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. *Lancet*. 2012;379(9826):1613-1620. doi:10.1016/S0140-6736(11)61930-2
- McCrindle B, Rowley A, Newburger J et al. Diagnosis, treatment and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. *Circulation*. 2017 Apr 25; 13(17):e927-e999
- Roberts SC, Jain S, Tremoulet AH, et al. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. *Contemp Clin Trials*. 2019;79:98-103. doi:10.1016/j.cct.2019.02.008
- Seaton K, Kharbanda A. Evidence-based management of Kawasaki disease in the emergency department. *Ped Emer Med Practice*. 2015 Jan 12:1
- Son M, Newburger J. Kawasaki disease. *Pediatr Rev*. 2013 Apr; 34(4): 151-6